Jazz Pharma beats estimates on record $1.2B quarterly revenue
Xywav and Epidiolex drive growth as company maintains 2026 revenue guidance of $4.25-4.5 billion
Jazz Pharmaceuticals shares rose in Tuesday trading after the biopharmaceutical company delivered better-than-expected quarterly results, fueled by strong performance from its key treatments Xywav and Epidiolex. The Dublin-based company reported fourth-quarter adjusted earnings per share of $6.64, exceeding analyst estimates of $5.85 by 13.5%, while revenue climbed to $1.2 billion—a 10% increase from the prior year and 8.1% above Wall Street projections of $1.11 billion.
The quarterly performance pushed full-year 2025 revenue to $4.3 billion, representing 5% year-over-year growth, according to the company's regulatory filing with the Securities and Exchange Commission. The results underscore Jazz's momentum in its core therapeutic areas, particularly in sleep medicine and rare diseases.
Xywav, the company's treatment for narcolepsy, emerged as a growth driver, with sales rising 12% to $1.7 billion for the full year. Meanwhile, Epidiolex, the first cannabis-derived medication approved by the U.S. Food and Drug Administration, achieved blockbuster status with annual sales of $1.1 billion, representing 9% growth. The performance demonstrates Jazz's ability to expand market penetration for both established and more recent product offerings.
Looking ahead, the company maintained its 2026 revenue guidance of $4.25 to $4.50 billion, signaling confidence in continued franchise growth. Management noted that it expects double-digit expansion across its key product lines in the coming year, positioning the company to extend its growth trajectory despite competitive pressures in specialty pharmaceuticals.
The stock, which traded up 0.3% to $173.83 following the announcement, has shown resilience in recent months. Shares are currently trading above their 50-day moving average of $167.45 and have recovered significantly from their 52-week low of $95.49, though they remain below the 52-week high of $182.99 reached earlier this year. The company's market capitalization stands at approximately $10.5 billion.
Analysts have maintained a predominantly positive outlook on Jazz Pharmaceuticals, with 15 rating the stock a buy or strong buy and just one recommending a hold. The consensus price target of $219.40 suggests significant upside potential from current levels, reflecting confidence in the company's pipeline and commercial execution capabilities.
The earnings beat comes at a time when biopharmaceutical companies face increasing scrutiny over drug pricing and pipeline risks. However, Jazz's diversified portfolio spanning neuroscience and oncology has provided some insulation from sector-specific headwinds. The company's forward price-to-earnings ratio of 6.90 remains attractive relative to industry peers, potentially supporting investor interest amid broader market volatility in healthcare stocks.
Investors will be watching for updates on Jazz's development pipeline, particularly in areas such as sleep medicine and rare diseases where the company has established commercial infrastructure. The ability to maintain growth momentum while investing in new therapies will be critical to sustaining the stock's recent recovery and meeting analyst expectations for continued outperformance.